David Miklos, MD

Articles

The Emerging Role of Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL

January 27th 2025

An analysis of key updates on CAR T-cell therapy in DLBCL from ZUMA-7 and TRANSFORM trials, exploring its potential as a primary second-line option, along with insights into efficacy and safety data for transplant-ineligible patients from ALYCANTE and PILOT studies

Second-line Treatment Landscape in Relapsed/Refractory DLBCL

January 27th 2025

A concise discussion of second-line treatment options for DLBCL, focusing on preferred regimens for transplant-eligible and ineligible patients, and tailored approaches based on relapse timing.

Role of Testing in Treatment Decisions - ClonoSeq, PhaseSeq, MRD+Disease

January 20th 2025

A concise discussion of second-line treatment strategies for DLBCL, highlighting preferred regimens for transplant-eligible and ineligible patients, as well as treatment approaches based on the timing of relapse.

Future Considerations for Front-line Treatment of DLBCL

January 20th 2025

An overview of key studies and updates from ASH 2024 offering new insights into subsequent treatment strategies and safety management in the first-line setting for DLBCL.

The Evolving First-line Treatment Approach for DLBCL

January 15th 2025

An exploration of how first-line treatment practices for DLBCL have evolved with new options, emphasizing the role of relapsed/refractory disease risk in guiding treatment selection.

Insights from POLARIX: How do Novel Perspectives Influence Treatment Outcomes in DLBCL?

January 15th 2025

An expert discussion on evolving first-line treatment strategies for newly diagnosed diffuse large B-cell lymphoma (DLBCL), incorporating insights from the 2024 NCCN guidelines, unmet needs in 1L therapies, and the impact of POLARIX trial updates on the use of Pola+R-CHP in clinical practice.

Emerging Updates in Front-line Treatment Approach of DLBCL

January 3rd 2025

Matthew Matasar, MD and Nilajan Ghosh, MD, PhD, discuss first-line treatment strategies for DLBCL, including factors influencing treatment selection, unmet needs in first-line treatment options, the impact of the 2024 NCCN guideline updates, and practical guidance for community practitioners following insights from the POLARIX trial.

Future of R/R DLBCL

March 2nd 2023

A panel of experts discuss the future of R/R DLBCL treatment and review some recent data from the 2022 ASH meeting.

Potential Role of CAR T-cell Therapy in the Front-line Setting for Patients with R/R DLBCL

March 2nd 2023

Experts discuss the potential use of CAR T-cell therapy in the front line setting as well as reviewing the use of tafasitamab from the FRONT-MIND and FIRST-MIND trials.

Sequencing Therapies in Patients with R/R DLBCL

February 22nd 2023

Insightful discussion among a panel of oncologists on how to best sequence therapies for patients with R/R DLBCL.

ZUMA-7: Clinical Implications

February 22nd 2023

Experts review some of the safety outcomes from the ZUMA-7 trial as well as discussing the clinical implications of the ZUMA-7 trial into their practice.

Eligibility Criteria for CAR T-Cell Therapy in R/R DLBCL

February 15th 2023

An overview of the ZUMA-7 and the TRANSFORM trial as well as reviewing eligibility criteria for patients who might receive CAR-T therapy.

Role of CAR T-cell Therapy in Patients with R/R DLBCL

February 15th 2023

Panel of experts discuss where CAR T-cell therapy might fit into the treatment landscape for patients with R/R DLBCL.

L-MIND: Review of Long-Term Analyses Data

February 8th 2023

Comprehensive insight into the L-MIND trial including a review of efficacy outcomes as well as discussing the implications of the data into clinical practice.

Treatment Options for Patients with R/R DLBCL

February 8th 2023

Experts discuss which factors are considered when choosing treatment options for patients with R/R DLBCL as well as reviewing the mechanism of tafasitamab.

An Overview of R/R DLBCL

February 1st 2023

Insightful discussion among experts into a brief overview of relapsed/refractory DLBCL (R/R DLBCL).

Front-Line Treatment Options for Patients with DLBCL

February 1st 2023

Expert oncologists provide a brief overview of front-line treatment options for patients diagnosed with double large b-cell lymphoma (DLBCL).